





131-Year History

Since its founding in 1890, Santen has contributed to patients and their loved ones. The spirit of our CORE PRINCIPLE, reflected in our company name, has more than 130 years of heritage. We have turned the challenges we have overcome into our strengths, and this continues to pave the way for our next growth trajectory.

Establishment -Laying the Foundation

(1890-1989)

Growth (1990-2009)

Transformation (2010-)

1890

Santen kicks off by taking the challenge of contributing to people's health

Santen's origins date back to 1890, when Kenkichi Taguchi opened Taguchi Santendo. Heburin-gan, a cold medication, was

its main product at the time. In the late 19th century, many people in Japan suffered from eye disorders, and demand for eye drops was high. The company launched Daigaku Eye Drops in 1899 and the product's popularity spread nationwide. From that point, Santen began taking on the challenge of contributing to eye health.





1950s

Pursuing a strategy centered on eye drops, and expanding into prescription pharmaceuticals

Due to difficulties encountered from aerial bombings during World War II, Santen shifted its business strategy focusing on eye drops. In 1958, Santen entered the prescription pharmaceutical business and in 1962 launched Mydrin-P, which promotes mydriasis, or dilation of the pupil. This groundbreaking eye drop used in ophthalmic surgery and diagnosis contributed significantly to the development of ophthalmology in Japan. Thereafter, product launches included an innovative antibiotic oph-

thalmic and a glaucoma treatment. laying the foundation to support ophthalmic treatment in Japan.



1990s

Strengthening the global production system toward internationalization and entering the European market

Upon its centennial in 1990, Santen embarked on a new growth stage with the announcement of a long-term vision to contribute to society with the best products and services focusing on the eye and health. In addition to business growth in Japan on the back of an expanding product lineup, and the completion of the Shiga

Plant, Santen entered the European market and emphasized aggressive business development to contribute to patients around the world.



2000s

Expanding solutions and building a business foundation in

Santen focused on meeting the needs of more people by providing a wide range of treatment options including intraocular lenses and supplements in addition to ophthalmic solutions for eye diseases. At the same time, the Company worked to build a business foundation in Asia, which included building a direct sales

network in China as well as completing the Suzhou Plant, and establishing Group company in South Korea.



2010s

Rapidly accelerating globalization to contribute to eye health worldwide

Aiming to become a specialized pharmaceutical company with a global presence as its long-term vision up to 2020, Santen rapidly accelerated its globalization, centered on China, Asia and EMEA. In 2015, Santen sold its anti-rheumatic pharmaceuticals business to AYUMI Pharmaceutical Corporation to specialize in ophthal-

mology and concentrate its management resources in the field.



2020s

Aspiring to Become A Social Innovator to deliver happiness through vision

Aiming to resolve eye-related social issues, the Company announced Santen 2030, a long-term vision toward 2030 and beyond. To realize "The Happiest Life for every individual through the Best Vision Experience," Santen continues to take on challenges worldwide to provide products and services with true value by bringing together knowhow and expertise through part-

nerships with external organizations, M&A and other approaches.





131-Year History

A Brief History of Santen's Product Innovation (Major products based on year of launch)



1890 Heburin-gan (cold medication)



1962 Mydrin-P (mydriatic)



Tarivid (anti-infective ophthalmic)



1992 Kary Uni (treatment for early-stage senile cataracts)



2008 **Tapros** (treatment for glaucoma and ocular hypertension)



Diquas (treatment for dry eve syndrome)



2019 2018 Eybelis **LENTIS Comfort** (treatment for glaucoma (intraocular lens)



Daigaku Eye Drops



1962 Super Sante



1991 Sante FX



1995 Hyalein (treatment for corneal disorders)



2000

Cravit

(anti-infective

ophthalmic)

2001 Livostin (anti-allergy ophthalmic)



2010 Cosopt (treatment for glaucoma and ocular hypertension)



and ocular hypertension)

Ikervis (treatment for severe keratitis in adult patients with dry eye disease)



Alesion LX (anti-allergy ophthalmic)

FY2020 revenue

JPY **249.6** billion

Overseas

32%

Japan ratio

68%

► Group Companies Country/Region and year of establishment indicated in parentheses Revenue Revenue in Japan Santen UK Limited (U.K. - 2014) Chongqing Santen Kerui Pharmaceutical Santen Holdings U.S. Inc. (U.S. · 2002) Co., Ltd. (China · 2016) Santen S.A.S. (France · 20111) Overseas revenue Santen Inc. Santen Pharmaceutical (China) Co., Ltd. - Santen SA (Switzerland · 2014²) Santen Holdings EU B.V. Advanced Vision Science, Inc. Santen Pharmaceutical Sales and (Netherlands · 2012) Marketing (Sozhou) Co., Ltd. (China · 2013) - SantenPharma AB (Sweden - 1997) Santen China Investment Co., Ltd. Santen Oy (Finland - 1997) Santen Pharmaceutical Korea Co., Ltd. SANTEN LIMITED LIABILITY COMPANY FY2010 revenue Santen GmbH JPY **110.8** billion - Santen Canada Inc. - Santen Italy S.r.l. (Canada · 2019) Santen Ventures, Inc. FY2000 revenue Santen Eye Care Co., Ltd. Santen Pharmaceutical JPY 88.4 billion InnFocus, Inc. Spain, S.L. Claire Co., Ltd. (Japan · 1997) - Eyevance Pharmaceuticals LLC anten Pharmaceutical Co., Ltd. (Japan · 1890) **Evevance Pharmaceuticals** Holdings Inc. Santen Business Santen India Private Limited (India · 2011) Services Co., Ltd. SANTEN (THAILAND) CO., LTD. (Thailand · 2014) -SANTEN PHARMA MALAYSIA SDN. BHD. Taiwan Santen Pharmaceutical Co., Ltd. (Taiwan · 1992*) Santen Pharmaceutical Asia Pte. Ltd. SANTEN PHARMACEUTICAL (HONG KONG) LIMITED (Hong Kong - 2016)

SANTEN PHILIPPINES INC. (Philippines · 2014) Santen Pharmaceutical Vietnam Co., Ltd. (Vietnam · 2020)



¹ Established as Novagali Pharma S.A. ² Established as Santen Switzerland SA ³ Established as TAHMIN SANTEN CO., LTD.